We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Merck & Co Inc | LSE:0QAH | London | Ordinary Share | MERCK & CO ORD (CDI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 101.40 | 96.00 | 106.40 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 0.00 | 13:18:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 60.12B | 365M | 0.1440 | 701.53 | 256.95B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/12/2024 | 21:26 | ALNC |  Merck agrees USD1.9 billion deal with Hansoh to develop obesity drug |
| 11/12/2024 | 19:40 | ALNC | IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results |
| 11/12/2024 | 16:02 | ALNC | *Astrazencea and Merck & Co to continue trialling lynparza across multiple.. |
| 12/11/2024 | 19:50 | ALNC | IN BRIEF: Merck trial shows Koselugo effective in treating adults |
| 31/10/2024 | 11:54 | ALNC | Merck cuts earnings guidance as acquisitions weigh on bottom line |
| 17/9/2024 | 19:15 | ALNC | IN BRIEF: Merck and Daiichi Sankyo's patritumab effective in phase 3 |
| 30/7/2024 | 11:59 | ALNC | TOP NEWS: Merck swings to second-quarter profit; trims profit guidance |
| 29/5/2024 | 13:22 | ALNC | Merck & Co enhances ophthalmology portfolio with EyeBio acquisition |
| 25/4/2024 | 11:13 | ALNC | Merck & Co raises annual outlook thanks to first quarter boost |
| 15/3/2024 | 15:23 | ALNC | IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda |
1 Year Merck & Chart |
Intraday Merck & Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
